汇宇制药：公司产品注射用帕瑞昔布钠、注射用培美曲塞二钠获得荷兰和沙特阿拉伯上市许可

Core Viewpoint - The company has received marketing approvals for its products from regulatory authorities in the Netherlands and Saudi Arabia, enhancing its international market presence and product pipeline [1] Group 1: Product Approvals - Seacross Pharma (Europe) Ltd. and Seacross Pharmaceuticals Ltd., subsidiaries of the company, have obtained marketing licenses for injectable Parecoxib Sodium and injectable Pemetrexed Disodium [1] - Injectable Parecoxib Sodium is indicated for the treatment of short-term postoperative pain in adults [1] - Injectable Pemetrexed Disodium, in combination with Cisplatin, is approved for first-line treatment of unresectable malignant pleural mesothelioma and locally advanced or metastatic lung cancer (primarily non-squamous) [1] Group 2: Market Impact - The approvals are expected to enrich the company's product pipeline in international markets [1] - These developments will enhance the company's brand image and facilitate the continuous expansion of its international business [1]